Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trials (PDQ®)

A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Basic Trial Information
Trial Description
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IBiomarker/Laboratory analysis, TreatmentActive18 and overPharmaceutical / IndustryA8081001
PROFILE 1001, NCT00585195

Trial Description


PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.

Eligibility Criteria

Inclusion Criteria:

  • Advanced malignancies (except leukemias), histologically proven at diagnosis; Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS
  • Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients with non-measurable disease may enter on a case-by-case basis); not required for DDI sub-studies.
  • Adequate blood cell counts, kidney function, liver function and Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG score of 2 may be allowed on a case-by-case basis)

Exclusion Criteria:

  • Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of starting study treatment, depending on the patient cohort
  • Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma
  • Active or unstable cardiac disease or heart attack within 3 months of starting study treatment

Trial Contact Information

Trial Lead Organizations/Sponsors

Pfizer Incorporated

Pfizer Call CenterStudy Director

Pfizer Call CenterPh: 1-800-718-1021

Trial Sites

 Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
 University of California, Irvine Medical Center Pharmacy
 Drug Shipment: Anschutz Cancer Pavilion
 University of Colorado Cancer Center at UC Health Sciences Center
 University of Chicago Cancer Research Center
 Beth Israel Deaconess Medical Center
 Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
 Joslin Beetham Eye Institute
 Massachusetts General Hospital
 Barbara Ann Karmanos Cancer Institute
 Kresge Eye Institute
New York
 Memorial Sloan-Kettering Cancer Center
  New York
 Memorial Sloan-Kettering Cancer Center
North Carolina
  Chapel Hill
 UNC Cancer Hospital
 UNC Hospitals
 Ohio State Eye and Ear Institute
 The James Cancer Hospital and Solove Research Institute
 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
 The Ohio State University Martha Morehouse Medical Plaza
 UPMC Cancer Centers
 Henry-Joyce Cancer Clinic
 Vanderbilt Eye Institute
 Vanderbilt-Ingram Cancer Center
  East Melbourne
 Peter MacCallum Cancer Centre
Republic of Korea
 Seoul National University Hospital

Link to the current record.
NLM Identifer NCT00585195 processed this data on April 20, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to

Back to TopBack to Top